CB 1 blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans

International Journal of Obesity

Volumn 37, Issue 5, 2013, Pages 699-703

  Bergholm, R ^a,b   Sevastianova, K ^a,b   Santos, A ^a,b   Kotronen, A ^a,b   Urjansson, M ^a,b   Hakkarainen, A ^b   Lundbom, J ^b   Tiikkainen, M ^a,b   Rissanen, A ^b   Lundbom, N ^b   Yki Jarvinen H ^a,b  

^a MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

adipose tissue; endocannabinoids; non alcoholic fatty liver disease; rimonabant

Indexed keywords

PLACEBO; RIMONABANT;

ABDOMINAL FAT; ADIPOSE TISSUE; ADULT; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; LIVER FAT; LOW CALORY DIET; MALE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; WEIGHT REDUCTION;

ADULT; AGED; CANNABINOID RECEPTOR ANTAGONISTS; DOUBLE-BLIND METHOD; FATTY LIVER; FEMALE; FINLAND; HUMANS; LIVER; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PIPERIDINES; PYRAZOLES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WEIGHT LOSS;

MUS;

EID: 84877579741     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2012.116     Document Type: Article

References (26)

1. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-530.
2. Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 2010; 55: 560-578.
3. Yki-Jarvinen H. Liver fat in the pathogenesis of insulin resistance and type 2 diabetes. Dig Dis 2010; 28: 203-209.
4. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887.
5. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3: 771-784.
6. Ravinet TC, Delgorge C, Menet C, Arnone M, Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004; 28: 640-648.
7. Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong WI et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008; 118: 3160-3169.
8. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. NewEngl J Med 2005; 353: 2121-2134.
9. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397.
10. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. J Am Med Assoc 2006; 295: 761-775.
11. Despres JP, Ross R, Boka G, Almeras N, Lemieux I. Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol 2009; 29: 416-423.
12. Tiikkainen M, Bergholm R, Vehkavaara S, Rissanen A, Hakkinen AM, Tamminen M et al. Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes 2003; 52: 701-707.
13. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480.
14. Ryysy L, Hakkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000; 49: 749-758.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
16. Larson-Meyer DE, Heilbronn LK, Redman LM, Newcomer BR, Frisard MI, Anton S et al. Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care 2006; 29: 1337-1344.
17. Shah K, Stufflebam A, Hilton TN, Sinacore DR, Klein S, Villareal DT. Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity 2009; 17: 2162-2168.
18. Szczepaniak LS, Babcock EE, Schick F, Dobbins RL, Garg A, Burns DK et al. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol 1999; 276: E977-E989.
19. Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 2007; 46: 122-129.
20. Hezode C, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A, Bouvier-Alias M et al. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 2008; 134: 432-439.
21. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54: 2838-2843.
22. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006; 55: 3053-3060.
23. Westerbacka J, Kotronen A, Fielding BA, Wahren J, Hodson L, PerttilaJ et al. Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease. Gastroenterology 2010; 139: 1961-1971.
24. Kantartzis K, Thamer C, Peter A, Machann J, Schick F, Schraml C et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 2009; 58: 1281-1288.
25. Kirk E, Reeds DN, Finck BN, Mayurranjan SM, Patterson BW, Klein S. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 2009; 136: 1552-1560.
26. Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 2010; 376: 517-523.